Fig. 2

Evidence collated during the process of NOACs inclusion into the 21st WHO Model List of Essential Medicines: this table shows the risks of major bleeding in non-valvular AF patients treated by NOACs versus warfarin in non-valvular AF patients. As overall NOACs had lower major bleeding and intracranial hemorrhage (ICH) in comparison with warfarin. DOI: http://doi.org/10.5334/gh.608